EN DE
Watch Great Novel Therapeutics Biotech & Medicals for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Great Novel Therapeutics Biotech & Medicals (7427) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Great Novel Therapeutics Biotech & Medicals stock TWD 31.17, price TWD 54.50, that is 42.8% below the price, quality 23 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0007427007

GN Great Novel Therapeutics Biotech & Medicals logo Thin data Nov 16, 2026

Great Novel Therapeutics Biotech & Medicals

7427 · TWO

Far too expensive (fair value 43% below the price) and weak company.

Get notified free when this changes
Expensive Growth (revenue 3y +30.7 %/yr in TWD) 
Mixed vs. peers (3/6) 
Fair value 31.17 TWD · Strongly overvalued 
Quality 23/100 
Negative free cash flow 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch Great Novel Therapeutics Biotech & Medicals for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

78.00 TWD 30.00 TWD Fair Value 31.17 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

12‑month range 30.00 TWD – 78.00 TWD · fair‑value band 23.38 TWD – 38.97 TWD · the 54.50 TWD price screens above the 31.17 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Great Novel Therapeutics Biotech & Medicals in your weekly email

Every Wednesday you see whether Great Novel Therapeutics Biotech & Medicals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan.

Show moreShow less

The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity.

It is also developing Kepida to treat HR+/her-2 advanced breast cancer and Peripheral T-cell lymphoma. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was incorporated in 2013 and is based in Taipei, Taiwan.

Stock analysis

Great Novel Therapeutics Biotech & Medicals (7427) currently trades at 54.50 TWD, while our estimate is 31.17 TWD, 43% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 23.38 TWD (bear) to 38.97 TWD (bull), the price of 54.50 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Great Novel Therapeutics Biotech & Medicals reported revenue of 1.2M TWD in FY2025 versus 630K TWD in FY2021, a compound +17.6%/yr. Reported net income was −97.5M TWD in FY2025.

Key figures

Market cap 2.9B TWD (≈ $87.3M) Micro · EPS (TTM) −2.45 TWD · Return on equity −17.0% · Return on assets (EBIT) −15.5% (5-year average) · Operating margin −1,092% · Revenue growth (YoY) +803% · Free cash flow −91.1M TWD · Net cash 145M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 30% below its 52-week high and 82% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −43%, 7427 screens richer than that median.

Fair Value

Bear 23.38 TWD Fair Value 31.17 TWD Bull 38.97 TWD
Price 54.50 TWD · Downside -42.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 23/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 15
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 80
Debt, balance sheet and risk of trouble
Investment 27
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 52
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 74
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−28.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−5,797.0% (2021) → −8,260.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

7427 screens overvalued: fair value 43% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Great Novel Therapeutics Biotech & Medicals with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 23 · Bottom 25%
Fair Value upside −42.8% · Bottom 25%
Profitability
Return on assets −18.5% · Above median
Growth and dividend
Revenue growth (quarter YoY) 803.1% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 5.73× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 2
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $957.76 $1,275 +33% vs 7427
Vertex Pharmaceuticals Incorporated VRTX $534.20 $592.46 +11% vs 7427
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs 7427
argenx SE ARGX $947.52 $908.40 −4% vs 7427
CSL Limited CSL A$199.55 A$186.49 −7% vs 7427
Moderna, Inc MRNA $206.80 $135.64 −34% vs 7427
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs 7427
Revolution Medicines, Inc RVMD $162.69 $88.78 −45% vs 7427
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs 7427
Royalty Pharma plc RPRX $68.68 $19.01 −72% vs 7427

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Great Novel Therapeutics Biotech & Medicals: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Great Novel Therapeutics Biotech & Medicals Fair Value". https://www.fairvalue-calculator.com/stock/7427

Frequently asked questions

Is Great Novel Therapeutics Biotech & Medicals (7427) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 31.17 TWD versus a price of 54.50 TWD, about 43% lower (overvalued).
What is the fair value of 7427?
Our estimate for Great Novel Therapeutics Biotech & Medicals is 31.17 TWD (as of Nov 16, 2026), built from audited fundamentals. The current price: 54.50 TWD.
What is the quality score of 7427?
Great Novel Therapeutics Biotech & Medicals has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Great Novel Therapeutics Biotech & Medicals (7427)?
Our calculated price target is the estimate of 31.17 TWD (as of Nov 16, 2026). Cautious scenario 23.38 TWD, optimistic scenario 38.97 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Great Novel Therapeutics Biotech & Medicals stock forecast for 2026?
Our estimate puts fair value at 31.17 TWD, about 43% lower versus a price of 54.50 TWD (overvalued). Cautious scenario 23.38 TWD, optimistic scenario 38.97 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Great Novel Therapeutics Biotech & Medicals (7427)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Great Novel Therapeutics Biotech & Medicals it is 31.17 TWD per share (as of Nov 16, 2026), against a price of 54.50 TWD.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 7427 trades above its calculated fair value: price 54.50 TWD, fair value 31.17 TWD, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7427?
No. The price is what the market pays today (54.50 TWD); the fair value is what the company's own numbers justify (31.17 TWD). For Great Novel Therapeutics Biotech & Medicals the two are 23.33 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Great Novel Therapeutics Biotech & Medicals worth?
The market values Great Novel Therapeutics Biotech & Medicals at about 2.9B TWD (market capitalisation, as of Nov 16, 2026). Per share that is 54.50 TWD; our models calculate a fair value of 31.17 TWD per share.
What do the bullish and bearish scenarios say about 7427?
Our models span a range for Great Novel Therapeutics Biotech & Medicals: cautious scenario 23.38 TWD, base 31.17 TWD, optimistic 38.97 TWD per share (as of Nov 16, 2026, price 54.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Great Novel Therapeutics Biotech & Medicals (7427)?
Balance-sheet figures for Great Novel Therapeutics Biotech & Medicals (as of Nov 16, 2026): return on equity −17.0%. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is 7427 from its 52-week high?
Great Novel Therapeutics Biotech & Medicals trades at 54.50 TWD, about 30% below its 52-week high of 78.00 TWD and 82% above the low of 30.00 TWD (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 31.17 TWD is for.
Which stocks are comparable to Great Novel Therapeutics Biotech & Medicals?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Great Novel Therapeutics Biotech & Medicals stock attractive at the current price?
The data as of Nov 16, 2026: price 54.50 TWD, calculated fair value 31.17 TWD (−43%), Quality Score 23/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Great Novel Therapeutics Biotech & Medicals itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Great Novel Therapeutics Biotech & Medicals (7427)?
The closing price on Nov 17, 2026 was 54.50 TWD. Our estimate is 31.17 TWD, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Great Novel Therapeutics Biotech & Medicals right now?
The price sits above even our optimistic bull case (38.97 TWD). The favourable scenario is already priced in. Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Great Novel Therapeutics Biotech & Medicals

How large is the market capitalisation of Great Novel Therapeutics Biotech & Medicals (7427)?
The market capitalisation of Great Novel Therapeutics Biotech & Medicals is 2.9B TWD (≈ $87.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Great Novel Therapeutics Biotech & Medicals (7427)?
Earnings per share at Great Novel Therapeutics Biotech & Medicals are −2.45 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Great Novel Therapeutics Biotech & Medicals (7427)?
The return on equity (ROE) of Great Novel Therapeutics Biotech & Medicals is −17.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Great Novel Therapeutics Biotech & Medicals (7427)?
On an EBIT basis the return on assets of Great Novel Therapeutics Biotech & Medicals is −15.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Great Novel Therapeutics Biotech & Medicals (7427)?
The operating margin of Great Novel Therapeutics Biotech & Medicals is −1,092% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Great Novel Therapeutics Biotech & Medicals (7427)?
Revenue at Great Novel Therapeutics Biotech & Medicals is growing 803% versus a year earlier (3y avg +30.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Great Novel Therapeutics Biotech & Medicals (7427) generate?
The free cash flow of Great Novel Therapeutics Biotech & Medicals is −91.1M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Great Novel Therapeutics Biotech & Medicals (7427) hold?
Great Novel Therapeutics Biotech & Medicals holds more cash than debt, 145M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Great Novel Therapeutics Biotech & Medicals in the live analysis

One click puts Great Novel Therapeutics Biotech & Medicals on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.